This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management of pruritus of PBC/biliary tract obstruction

Authoring team

Pruritus associated with cholestasis secondary to primary biliary cirrhosis is managed with the following:

  • as first line treatment - cholestyramine, 4-8 g daily, taken at least 1 hour before or 4-6 hours after other medication (1). Cholestyramine may reduce the absorption of vitamin D and so worsen osteomalacia.
  • Rifampicin should be considered as a second-line treatment option although discolouration of urine, tears and other body secretions is seen during treatment (1).
  • Naltrexone is regarded as the third line treatment option
  • for patients who are resistant to above treatment methods, Sertraline may be used as fourth line treatment (1).

Use of ursodeoxycholic acid (UDCA) has been beneficial in cholestatic itch due to intrahepatic cholestasis of pregnancy (1).

Cholestyramine may reduce the absorption of vitamin D and so worsen osteomalacia. Consider UV light treatment or plasmapheresis, which also benefits xanthomata and xanthomatous neuropathy.

Cholestatic itch due to obstructive bile duct lesions is managed with either endoscopic, radiological or surgical correction treatment (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.